Roivant Sciences Ltd.
ROIV
$10.85
$0.191.78%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.28% | 8.37% | -8.65% | -14.13% | 18.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.28% | 8.37% | -8.65% | -14.13% | 18.42% |
| Cost of Revenue | 61.46% | 37.05% | 22.48% | 12.10% | -36.76% |
| Gross Profit | -57.43% | -30.24% | -18.26% | -8.13% | 36.00% |
| SG&A Expenses | 82.36% | 38.10% | 8.38% | -5.17% | -54.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.57% | 0.25% | -13.50% | -20.85% | -23.11% |
| Operating Income | -20.88% | 0.21% | 13.80% | 21.23% | 24.76% |
| Income Before Tax | -114.35% | 644.16% | 600.44% | 528.18% | 449.16% |
| Income Tax Expenses | -137.04% | 389.38% | 329.60% | 103.93% | 209.25% |
| Earnings from Continuing Operations | -114.22% | 635.03% | 593.89% | 522.80% | 444.84% |
| Earnings from Discontinued Operations | 263.89% | 92.60% | 32.34% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 97.17% | 48.84% | 28.16% | 48.66% | -14.04% |
| Net Income | -102.61% | 589.95% | 588.74% | 531.00% | 458.61% |
| EBIT | -20.88% | 0.21% | 13.80% | 21.23% | 24.76% |
| EBITDA | -22.13% | -0.67% | 13.72% | 21.64% | 25.59% |
| EPS Basic | -102.48% | 554.70% | 541.28% | 476.90% | 411.85% |
| Normalized Basic EPS | -12.11% | 24.86% | 30.88% | 32.79% | 61.38% |
| EPS Diluted | -102.92% | 526.76% | 513.83% | 452.04% | 392.20% |
| Normalized Diluted EPS | -13.57% | 25.77% | 31.63% | 33.42% | 61.87% |
| Average Basic Shares Outstanding | -1.51% | 4.03% | 7.77% | 11.03% | 8.61% |
| Average Diluted Shares Outstanding | -2.91% | 5.51% | 9.29% | 12.58% | 10.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
